Brain Stimulation for Opioid Use Disorder
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether a non-invasive brain stimulation technique, transcranial direct current stimulation (tDCS), can reduce opioid cravings and prevent relapse. Participants will undergo five sessions where tDCS targets specific brain areas linked to decision-making and self-control. Two groups will participate: one will receive active stimulation, and the other will receive a sham (fake) version. Ideal candidates are those currently dealing with opioid dependence and who recently started treatment with medications like buprenorphine or methadone. As an unphased trial, this study offers participants the chance to contribute to pioneering research that could lead to innovative treatments for opioid dependence.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, it requires recent initiation of buprenorphine or methadone, so you may need to continue these medications during the trial.
What prior data suggests that this brain stimulation technique is safe for opioid use disorder?
Research has shown that transcranial direct current stimulation (tDCS) is generally safe and low-risk. Studies have found it can help reduce cravings for opioids and other drugs like methamphetamine and cocaine. Past evaluations described tDCS as a noninvasive way to adjust brain activity without major side effects.
Participants in earlier studies reported tDCS as a well-tolerated treatment, with few instances of discomfort or negative effects. This treatment has been used not only for substance use disorders but also for managing chronic pain, demonstrating its versatility and safety across different conditions. Although side effects are rare, they may include mild headaches or skin irritation where the electrodes are placed.12345Why are researchers excited about this trial?
Researchers are excited about transcranial Direct Current Stimulation (tDCS) for opioid use disorder because it offers a novel approach compared to traditional treatments, which often include medications like methadone or buprenorphine. Unlike these medications, tDCS is a non-invasive brain stimulation technique that targets the dorsolateral prefrontal cortex (DLPFC), a region involved in cognitive control and decision-making. This method could potentially enhance cognitive function and reduce cravings without the need for medication. Additionally, tDCS sessions are relatively quick and could fit easily into daily routines, making it a potentially convenient option for patients.
What evidence suggests that transcranial direct current stimulation is effective for opioid use disorder?
Research has shown that transcranial direct current stimulation (tDCS) may help reduce cravings for opioids. tDCS is a noninvasive method to stimulate the brain, and studies have found it can lessen the desire for substances like opioids, methamphetamine, cocaine, and tobacco. In this trial, participants will be assigned to either an active tDCS arm or a sham tDCS arm. A review of noninvasive brain stimulation methods found that tDCS could improve outcomes for people dealing with opioid use. By targeting brain areas related to cravings and self-control, tDCS might help decrease the urge to use drugs and support recovery. Early findings suggest tDCS could be a low-risk option for those with opioid use disorder.12346
Who Is on the Research Team?
Abrantes Abrantes, Ph.D.
Principal Investigator
Butler Hospital
Michael Stein, M.D.
Principal Investigator
Boston University
Are You a Good Fit for This Trial?
This trial is for individuals with Opioid Use Disorder. Participants should have a history of opioid dependency but are currently seeking treatment. The study excludes those who might have other medical conditions that could interfere with the trial or pose risks.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive five sessions of tDCS+CCN priming stimulation or sham tDCS+CCN priming over consecutive business days
Maintenance Treatment
Participants continue buprenorphine or methadone maintenance treatment while being monitored for opioid relapse and craving
Follow-up
Participants are monitored for long-term neurobehavioral outcomes, including opioid relapse and craving
What Are the Treatments Tested in This Trial?
Interventions
- tDCS
Find a Clinic Near You
Who Is Running the Clinical Trial?
Butler Hospital
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Collaborator